Tag: Biocon

Viatris and Biocon Biologics launch Abevmy, oncology biosimilar, in Canada

Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced May 19th, that Abevmy® (bevacizumab) is now...

Biocon Biologics gets EMA’s backing for Inpremzia

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., announced today the European Medicines Agency’s Committee for Medicinal Products...

Biocon to acquire Viatris’ biosimilars assets for up to $3.335 bln

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has entered into a definitive agreement with its...